Navigation Links
CTI Provides Update on New Product Acquisition Strategy and Upcoming ASCO Events
Date:5/25/2011

time/ 9:45 a.m. Pacific time and conclude at approximately 1:00 p.m. Central time /8:00 p.m. Central European time/11:00 a.m. Pacific time.  The presentations will be webcast live with slides at www.celltherapeutics.com.

About OPAXIO(TM)

OPAXIO™ (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX™, is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.

About Tosedostat

Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in phase I-II clinical trials. CTI has exclusive marketing and co-development rights to Chroma Therapeutics Ltd.'s drug candidate tosedostat in North, Central and South America.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.

Sign up for email alerts and get RSS feeds at our Web site, http
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
6. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Gen-Probe invests US$5 million in DiagnoCure SAN DIEGO and ... GPRO ) and DiagnoCure Inc. (TSX: CUR) today ... their 2003 license agreement, establishing new FDA submission milestones ... potential of the PCA3-based test for prostate cancer in ...
... 29 The recent announcement of the REDUCE trial results ... optimism to the prostate cancer community as dutasteride (Avodart), a ... lower by 23 percent the risk of prostate cancer in ... Network looks forward to this becoming an additional tool in ...
Cached Medicine Technology:Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 2Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 3Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 4Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests 5Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer 2
(Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
(Date:4/17/2014)... 2014While 94 per cent of Canadians surveyed said they ... for a specific number of genetic conditions, only 80 ... in screening that would sequence their newborns, genomes.,Most newborns ... their first day or two of life in which ... heels and tested for about five to 54 conditions, ...
(Date:4/17/2014)... for more research to be carried out into ... Africa. In a paper in The Lancet ... with colleagues in the department of Parasitology and ... Ohio, University of Cambridge and the Royal Veterinary ... burden of HIV/AIDS and schistosomiasis of children, and ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2
... rheumatoid arthritis (RA), an autoimmune disease marked by chronic ... and the incidence of cancer is complicated. Epidemiologic ... cancers are increased among RA patients, while breast and ... are caused by the nature of RA or by ...
... for downward social mobility, study confirms , , TUESDAY, Aug. ... a downscale neighborhood often go together, a new study ... comes first. , "The more alcohol problems a man ... in, or migrate into, a disadvantaged neighborhood," according to ...
... report cites drop in employer-sponsored coverage , , TUESDAY, ... Americans are without health insurance, according to new U.S. ... trend can be explained by employers who are curtailing ... workers to afford, the report said. , "The number ...
... better diagnoses and therapies, researchers say , , TUESDAY, Aug. ... the brains of multiple sclerosis patients may help predict ... researchers are reporting. , "This is a new ... the tissue of the patient,s lesions," said lead researcher ...
... age 7 were virtually erased, study finds , , TUESDAY, ... during pregnancy and don,t get treatment, their kids face ... suggests that treatment can essentially eliminate that risk. , ... obesity can be completely reversed in these children, said ...
... to be published in an upcoming edition of ... that Pycnogenol (pic-noj-en-all), pine bark extract from the ... as hot flashes, depression, panic attacks, cholesterol and ... transition. The results suggest Pycnogenol may serve as ...
Cached Medicine News:Health News:Biologic treatment for rheumatoid arthritis and the risk of cancer 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 3Health News:Record Number of Americans Lack Health Insurance 2Health News:Record Number of Americans Lack Health Insurance 3Health News:Record Number of Americans Lack Health Insurance 4Health News:Brain Lesions Predict MS Progression 2Health News:Brain Lesions Predict MS Progression 3Health News:Treating Diabetes During Pregnancy Could Lead to Thinner Kids 2Health News:New study: Pine bark reduces perimenopausal symptoms 2
Cold light source dual outlet....
The 9100 is a truly affordable 100 Watt xenon light source providing accurate color and brightness. This xenon light source is ideal for surgery centers, evaluations or general office use....
... the brightest and most versatile light source ... 300 Watts, this unique light source allows ... an illuminated instrument or two UltraLite Headlights ... delivers bright, white light that is as ...
Loupe KS is achieved by a special system carrier....
Medicine Products: